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Practical uses of nanomaterials are rapidly spreading to a wide variety of fields. However, potential harmful effects
of nanomaterials are raising concerns about their safety. Therefore, it is important that a risk assessment system is
developed so that the safety of nanomaterials can be evaluated or predicted. Here, we attempted to identify novel
biomarkers of nanomaterial-induced health effects by a comprehensive screen of plasma proteins using
two-dimensional differential in gel electrophoresis (2D-DIGE) analysis. Initially, we used 2D-DIGE to analyze changes
in the level of plasma proteins in mice after intravenous injection via tail veins of 0.8 mg/mouse silica nanoparticles
with diameters of 70 nm (nSP70) or saline as controls. By quantitative image analysis, protein spots representing
>2.0-fold alteration in expression were found and identified by mass spectrometry. Among these proteins, we
focused on hemopexin as a potential biomarker. The levels of hemopexin in the plasma increased as the silica
particle size decreased. In addition, the production of hemopexin depended on the characteristics of the
nanomaterials. These results suggested that hemopexin could be an additional biomarker for analyzing the
biological responses associated with exposure to silica nanoparticles. We believe that this study will contribute to
the development of biomarkers to ensure the safety of silica nanoparticles.
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Nanomaterials with particle sizes below 100 nm display
unique properties compared to conventional materials
with a submicron size. Various types of nanomaterials
have been designed and produced for consumer and in-
dustrial applications such as medicine, cosmetics, and
food [1,2]. As the use of nanomaterials increases, there
is a growing need to ensure their safety because their
unique properties might be associated with undesirable
biological interactions [3,4]. However, current knowledge
of the potential risk of nanomaterials is considered* Correspondence: yasuo@phs.osaka-u.ac.jp; ytsutsumi@phs.osaka-u.ac.jp
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reproduction in any medium, provided the originsufficient. Therefore, to facilitate the development of
nanomaterials as a safe and usable product, it is import-
ant to develop guidelines for evaluation of their safety
and efficacy.
Silica nanoparticles have been widely used in many
consumer products such as cosmetics, food, and medi-
cine because of their useful properties, including
straightforward synthesis, relatively low cost, easy separ-
ation, and easy surface modification [5,6]. However, re-
cent studies have found that silica nanoparticles induce
substantial lung inflammation and are cytotoxic to vari-
ous cell types [7,8]. Furthermore, our group showed that
silica nanoparticles penetrate the skin and produce sys-
temic exposure after topical application [9]. These find-
ings underscore the need to examine biological effects
after systemic exposure to silica nanoparticles. Our
group also demonstrated that intravenous injection of
silica nanoparticles with a diameter of 70 nm into miceis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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complications such as resorption and fetal growth re-
striction [13]. We also showed that these pregnancy
complications can be suppressed by amino or carboxyl
group surface modification [11,13].
The development of safe nanomaterials requires not
only an evaluation of safety, but also the ability to pre-
dict their biological effects. Molecular biomarkers con-
stitute an objective indicator for correlating against
various physiological conditions or variation of disease
state [14,15]. Biomarker studies have the potential to
provide valuable information to identify early biological
events associated with the adverse health effects of
engineered nanomaterials in a development stage more
easily and rapidly [16]. Studies of biomarkers for nano-
materials have barely advanced, but it is envisaged that a
biomarker profile for exposure to nanomaterials would
represent the unity of local and systemic physiological
responses induced as a result of exposure. Therefore,
there is a need to identify and evaluate biomarkers for
nanomaterials that would be suitable for predicting the
potential toxicity of nanomaterials as well as to facilitate
the development of nanomaterials that are safe. In this
regard, our previous study used sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis
to show that the acute-phase proteins, haptoglobin, C-
reactive protein, and serum amyloid A (SAA), can act as
useful biomarkers for analyzing the risk of exposure to
nanomaterials and their associated toxicity [17]. How-
ever, SDS-PAGE analysis has limited capacity for a com-
prehensive screen for biomarkers because it is based
only on differences in molecular weight of proteins.
Proteomics-based analyses such as two-dimensional
(2D) gel separation and mass spectrometry are more suit-
able approaches for such a comprehensive study. Here, we
performed a screen for biomarkers of nanomaterials using
two-dimensional differential in gel electrophoresis (2D-
DIGE), which is a gel-based approach like SDS-PAGE
but separates proteins on the basis of their molecular
weight and isoelectric point. We used this approach to
identify hemopexin as a potential biomarker for predict-
ing the biological effects induced by silica nanoparticles.Methods
Materials
Silica particles were purchased from Micromod Partikel-
technologie (Rostock/Warnemünde, Germany). Silica
particles with diameters of 70, 300, and 1,000 nm
(nSP70, nSP300, and mSP1000, respectively) and nSP70
with surface carboxyl and amino groups (nSP70-C and
nSP70-N, respectively), were used in this study. The sil-
ica particles were suspended in saline, sonicated for 5
min, and vortexed for 1 min prior to use.Animals
Female BALB/c mice were purchased from Nippon SLC,
Inc. (Shizuoka, Japan) and were used at 6 to 8 weeks of
age. The mice were housed in a ventilated animal room
maintained at 20 ± 2°C with a 12-h light/12-h dark cycle.
The mice had free access to water and forage (FR-2,
Funabashi farm, Chiba, Japan). All of the animal experi-
mental procedures used in this study were performed in
accordance with the Osaka University and National In-
stitute of Biomedical Innovation guidelines for the wel-
fare of animals.
2D-DIGE analysis
The BALB/c mice were treated intravenously with 0.8
mg/mouse nSP70 or saline. After 24 h, blood samples
were collected, and plasma was harvested by centrifu-
ging blood at 13,800×g for 15 min. ProteoPrep (Sigma-
Aldrich, Saint Louis, MO, USA) was used to remove
albumin and immunoglobulin from the plasma accord-
ing to the manufacturer's instructions. Plasma proteins
were purified from the plasma of the nSP70- or saline-
treated mice using a 2D-Clean up Kit (GE Healthcare
Biosciences, Piscataway, NJ, USA) and were labeled at
the ratio of 50 μg proteins:400 pmol Cy3 or Cy5
protein-labeling dye (GE Healthcare Biosciences) in
dimethylformamide according to the manufacturer's
protocol. Briefly, 50 μg of each labeled sample was
mixed with rehydration buffer (7 M urea, 2 M thiourea,
4% 3-(3-cholamidepropyl) dimethylammonio-1-propane-
sulphonate, 2% dithiothreitol, 2% Pharmalyte; GE
Healthcare Biosciences) and applied to a 24-cm immobi-
lized pH gradient gel strip (immobilized pH gradient
(IPG) strip pH 4 to 7 NL) for separation in the first di-
mension. Samples for the spot picking gel were prepared
without labeling by Cy dyes. For the second-dimension
separation, the IPG strips were applied to SDS-PAGE
gels (10% polyacrylamide and 2.7% N,N0-diallyltartardia-
mide gels). After electrophoresis, the gels were scanned
with a laser fluoroimager (Typhoon Trio, GE Healthcare
Biosciences). The spot picking gel was scanned after
staining with Deep Purple Total Protein Stain (GE
Healthcare Biosciences). Quantitative analysis of protein
spots was carried out with Decyder-DIA software (GE
Healthcare Biosciences). Protein spots representing
greater than twofold alteration in expression were picked
using an Ettan Spot Picker (GE Healthcare Biosciences).
In-gel tryptic digestion
The gel pieces were destained with 50% acetonitrile
(ACN)/25 mM NH4HCO3 for 10 min, dehydrated with
100% ACN for 10 min, and then dried using a centrifu-
gal concentrator (TOMY SEIKO, Tokyo, Japan). Next,
8 μl of 20 μl/ml trypsin solution (Promega, Madison,
WI, USA) diluted fivefold in 50 mM NH4HCO3 was
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night at 37°C. We used three solutions to extract the
resulting peptide mixtures from the gel pieces. First, 50
μl of 50% (v/v) ACN in 0.1% aqueous trifluoroacetic acid
(TFA) was added to the gel pieces, which were then
sonicated for 30 min. Next, we collected the solution
and added 80% (v/v) ACN in 0.1% TFA. Finally, 100%
ACN was added for the last extraction. The peptide
solutions were dried and resuspended in 10 μl of 0.1%
formic acid. The resulting peptide mixture was then ana-
lyzed by nano-flow liquid chromatography/tandem mass
spectrometry (maXis, Bruker Daltonik GmbH, Bremen,
Germany). The Mascot search engine (Matrix Science
Inc., Boston, MA, USA) was initially used to query the
entire theoretical tryptic peptide as well as the Swiss-
Prot protein sequence database.Measurement of hemopexin
The BALB/c mice were treated intravenously with 0.8
mg/mouse of the silica particles nSP70, nSP300,
mSP1000, nSP70-C, and nSP70-N or with saline. Blood
samples were collected at 2, 6, 24, 48, and 72 h after
treatment. For assessment of the sensitivity of hemo-
pexin levels to the concentration of silica particles, the
BALB/c mice were treated intravenously with 0.05, 0.2,
or 0.8 mg/mouse nSP70. After 24 h, blood samples were
collected, and plasma was harvested by centrifuging
blood at 13,800×g for 15 min. Plasma levels of hemo-
pexin were measured using a commercial enzyme-linked
immunosorbent assay (ELISA) kit (Life Diagnostics,
West Chester, PA, USA), according to the manufac-
turer's instructions.Plasma biochemistry
The BALB/c mice were treated intravenously with 0.8
mg/mouse nSP70 or saline. After 2, 6, 24, and 48 h,
blood samples were collected, and plasma was harvested
by centrifuging blood at 13,800×g for 15 min. Total
hemoglobin and heme in the blood of the nSP70-treated
mice were determined by BioAssay Systems Quanti-
ChromTM Assay Kits (BioAssay Systems, Hayward, CA,
USA). Also, plasma levels of total bilirubin (TBIL) and
direct bilirubin (DBIL) were measured by a biochemical
auto analyzer, FUJI DRI-CHEM 7000 (Fujifilm, Tokyo,
Japan), and the level of indirect bilirubin was calculated
from these values.Statistical analysis
All results are expressed as means ± standard error of
the mean (SEM). Statistical comparisons between groups
were performed by one-way analysis of variance
(ANOVA) with the Bonferroni test.Results
Characteristics of silica particles
Silica particles are well suited for studying the influence of
nanomaterial size on biodistribution and various biological
effects because they show much better dispersibility in
aqueous solutions than most other nanomaterials [18]. We
used three different-sized silica particles with diameters be-
tween 70 and 1,000 nm (nSP70, nSP300, and mSP1000)
and nSP70 with carboxyl (nSP70-C) and amino (nSP70-N)
surface functional groups. As we have described previously
[9,10,13], all silica nanoparticles were confirmed by trans-
mission electron microscopy to be smooth-surfaced
spheres. The hydrodynamic diameters of nSP70, nSP300,
and mSP1000 were 65, 322, and 1,140 nm, respectively,
and their zeta potentials or overall surface potentials were
−53, −62, and −67 mV, respectively. For nSP70-C and
nSP70-N, the hydrodynamic diameters were 70 and 72
nm, respectively, and their zeta potentials were −76 and
−29 mV, respectively. These results indicate that the carb-
oxyl and amino surface modifications altered the surface
charge of the particles. The size distribution spectrum of
each set of silica particles showed a single peak, and the
measured hydrodynamic diameter corresponded almost
precisely to the primary particle size of each set of silica
particles. These results indicate that the silica particles used
in this study were well dispersed in solution.
2D-DIGE analysis and identification of differentially
expressed proteins
To identify protein biomarkers of nanomaterials in mice,
we analyzed changes in the levels of plasma proteins fol-
lowing treatment with nSP70 by using 2D-DIGE. Plasma
proteins isolated after treatment with saline or 0.8 mg/
mouse nSP70 were labeled with Cy3 and Cy5, respect-
ively, and were used for 2D-DIGE analysis. The reason
why we chose the dose of silica particles for treatment is
that none of the silica particles induced any significant
changes in the levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and blood urea
nitrogen and that all parameters remained within the
physiological range, as we have previously reported [17].
Quantitative image analysis revealed 59 spots showing
increased protein levels and 23 spots showing decreased
protein levels in the plasma of nSP70-treated mice com-
pared with controls. We selected a total of eight candi-
date spots showing the highest increases and decreases
in protein expression levels. Then, liquid chromatog-
raphy/time-of-flight/mass spectrometry (LC/TOF/MS)
analysis of the spots subsequently identified seven differ-
ent proteins (Figure 1). Among these proteins, haptoglo-
bin, hemopexin, and alpha-1-acid glycoprotein 1, which
are acute-phase proteins, displayed increased expression
in the plasma of nSP70-treated mice. Four proteins, in-










Figure 1 2D-DIGE image of fluorescent-labeled proteins.
Proteins from the plasma after treatment with saline or nSP70 were
labeled with Cy3 and Cy5, respectively, and used for performing 2D
electrophoresis.
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pression in the plasma of nSP70-treated mice (Table 1).
These findings are consistent with the results of our pre-
vious study identifying haptoglobin, showing the highest
level in this study, as a candidate biomarker using SDS-
PAGE analysis. We selected a candidate biomarker from
among the proteins which displayed increased expres-
sion at first. However, in the future, there is a need to
identify various biomarkers by evaluating candidate pro-
teins which displayed not only increased expression but
also decreased expression to improve the accuracy for
predicting the biological effects induced by nanomater-
ials. Here, we focused on hemopexin, which showed the
second highest expression level among the identified
candidate biomarkers after haptoglobin.
Plasma hemopexin levels after treatment with
silica particles
Hemopexin is known as an acute-phase protein, mainly
synthesized in the liver [19]. To assess the potential of
hemopexin as a biomarker, we examined whether thereTable 1 Identification of candidate proteins as biomarkers
Spot Protein name Accession number
1 Haptoglobin [Swiss-Prot:Q61646]
2 Hemopexin [Swiss-Prot:Q91X72]
3 Alpha-1-acid glycoprotein 1 [Swiss-Prot:Q60590]
4 Inter-alpha-trypsin inhibitor [Swiss-Prot:Q61703]
5 Complement C4-B [Swiss-Prot:P01029]
6 Cullin-4A [Swiss-Prot:Q3TCH7]
7 Serotransferrin [Swiss-Prot:Q921l1]
The differentially expressed spots were identified by LC/TOF/MS. pI, isoelectric poinwere time-dependent changes in the plasma levels of
hemopexin levels after treatment with different-sized sil-
ica particles. The BALB/c mice were treated intraven-
ously with 0.8 mg/mouse nSP70, nSP300, or mSP1000.
After 6, 24, or 72 h, we examined the plasma levels of
hemopexin by ELISA. We observed no changes in the
plasma levels of hemopexin in mice treated with nSP300
or mSP1000 over the time course of the experiment.
However, mice treated with nSP70 showed an increase
in plasma levels of hemopexin at 24 h after treatment,
and the plasma level of hemopexin in nSP70-treated
mice remained significantly higher than that of controls
at 72 h after treatment (Figure 2A). These results indi-
cate that the smaller the particle size, the greater the in-
crease in plasma levels of hemopexin induced by silica
particles. We then assessed the sensitivity of hemopexin
induction to lower concentrations of silica particles. The
BALB/c mice were treated intravenously with 0.05, 0.2,
or 0.8 mg/mouse nSP70. After 24 h, we examined the
plasma levels of hemopexin by ELISA and found that
the plasma level of hemopexin increased in a dose-
dependent manner (Figure 2B). These results indicate
that the level of induction of hemopexin is dependent
on the concentration of silica particles. Taken together,
these findings highlight the potential of hemopexin as a
valuable biomarker for analyzing the risk and toxicity of
exposure to silica nanoparticles. Now, to evaluate the
sensitivity of hemopexin to serve as a biomarker of a
more realistic exposure, we have assessed the response
of hemopexin to silica nanoparticles introduced via dif-
ferent routes.
Hemolytic activity of silica nanoparticles
Hemopexin is a heme-binding plasma glycoprotein that
forms the second line of defense against hemoglobin-
mediated oxidative damage during intravascular
hemolysis [20]. Intravascular hemolysis causes the re-
lease of massive amounts of hemoglobin and heme into
the plasma, where they are rapidly bound by haptoglobin
and hemopexin, respectively [21]. Because nSP70
induced an increase in the plasma levels of haptoglobin


































































Figure 2 Plasma levels of hemopexin after treatment with silica
particles. BALB/c mice were treated intravenously with 0.8 mg/
mouse nSP70, nSP300, or mSP1000. (A) After 6, 24, and 72 h, the
plasma levels of hemopexin in the mice were determined by ELISA.
(B) BALB/c mice were treated intravenously with 0.05, 0.2, or
0.8 mg/mouse nSP70. After 24 h, blood samples were collected. The
plasma levels of hemopexin in treated mice were determined by
ELISA. Data are presented as mean± SEM (n= 5; Double asterisks
denote P< 0.01 versus the value for saline-treated group by ANOVA).
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We assessed plasma levels of heme and hemoglobin 2, 6,
24, or 48 h after treatment of the BALB/c mice intraven-
ously with 0.8 mg/mouse of nSP70. At this dose, nSP70
did not induce any significant increases in the plasma
levels of heme (Figure 3A) or hemoglobin (Figure 3B) at
all time points.
During hemolysis, hemoglobin is released into the
plasma from damaged red blood cells and leads to an in-
crease in plasma levels of indirect bilirubin [22-24].
Thus, although nSP70 did not induce a significant in-
crease in the plasma levels of heme or hemoglobin, weinvestigated whether nSP70 induced hemolytic activity
that resulted in an increased plasma level of indirect bili-
rubin. Following treatment of mice with nSP70, we mea-
sured plasma levels of TBIL and DBIL and calculated
the level of indirect bilirubin from these values. We
found no changes in the plasma levels of TBIL
(Figure 3C), DBIL (Figure 3D), or indirect bilirubin
(Figure 3E) over the time course of the experiment.
Taken together, these results clearly show that nSP70
does not induce hemolytic activity in mice under these
conditions.
Surface modification of nSP70
Previously, we demonstrated that surface properties of
silica nanoparticles play an important role in determin-
ing their safety [11,13]. For instance, our group showed
that surface modification of nSP70 with amine or carb-
oxyl groups altered the intracellular distribution of the
nanoparticles, had an effect on cell proliferation [11],
and suppressed toxic biological effects of silica particles
such as inflammatory responses. To assess whether
hemopexin could predict the strength of toxicity induced
by silica nanoparticles, we examined the plasma levels of
hemopexin in the mice after administration of nSP70
with amino or carboxyl group surface modifications.
The BALB/c mice were treated intravenously with 0.8
mg/mouse of nSP70, nSP70-C, or nSP70-N. After 2, 6,
24, or 48 h, we examined the plasma levels of hemo-
pexin by ELISA. The mice treated with nSP70, nSP70-
C, and nSP70-N did not show any elevated level of
hemopexin at 2 or 6 h. At 24 h, the plasma level of
hemopexin in mice treated with nSP70-N was signifi-
cantly lower than that in mice treated with unmodified
nSP70. On the other hand, the plasma level of hemo-
pexin in mice treated with nSP70-C was similar to that
in nSP70-treated mice and significantly higher than
that in saline-treated mice (Figure 4A). At the same
time, the plasma levels of haptoglobin (Figure 4B) and
SAA (Figure 4C) in mice treated with nSP70-C were
significantly lower than those in nSP70-treated mice,
which is consistent with our previously reported
results [17]. These results indicate that there are differ-
ences in the mechanisms underlying the production of
hemopexin and other acute-phase proteins induced by
nSP70-C.
Discussion
By using biomarkers, we are able to predict not only the
present disease and clinical condition, but also the risk
of acquiring disease in the future. Therefore, it is neces-
sary to progress studies of biomarkers for nanomaterials
because very little information is available on the bio-
logical effects of nanomaterials. Here, we used 2D-DIGE






































































































































2 h 6 h 24 h 48 h
Figure 3 Hemolytic activity of silica nanoparticles. BALB/c mice were treated intravenously with 0.8 mg/mouse nSP70. After 2, 6, 24, and 48 h,
we examined the level of (A) total heme and (B) hemoglobin in the blood of treated mice. The levels of (C) TBIL and (D) DBIL were measured,
and (E) the level of indirect bilirubin was calculated from these values.
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We identified hemopexin (Table 1) as a useful bio-
marker for analyzing the biological responses associated
with exposure to silica nanoparticles. Because 2D-DIGE
is a proteomic method, this approach has potential
to uncover the as yet unknown biological effects of
nanomaterials.
On the other hand, an inherent disadvantage of 2D
electrophoresis is the poor resolution of hydrophobic
proteins [25,26]. Hence, it is likely that integral mem-
brane proteins are strongly underrepresented. Isobaric
tags for relative and absolute quantification or iTRAQ is
a comprehensive gel-free quantitative proteomic methodbased on mass spectrometry [27,28]. This approach can
be used to generate proteomic profiles that reflect the
pathological state of organs and aid in the early detec-
tion of diseases [29,30]. We envisage that a combination
of comprehensive proteomic methods would help to
identify potential toxicities of nanomaterials during their
development and contribute to the establishment of
strategies to ensure their safety.
Silica materials with amorphous particle morphology
are known to cause the hemolysis of mammalian red
blood cells [31,32]. For this reason, we investigated the
possibility that silica nanoparticles could induce






















































































Figure 4 Responses of hemopexin by the exposure to surface
modified nSP70. BALB/c mice were treated intravenously with
nSP70 modified with amino (nSP70-N) or carboxyl (nSP70-C) groups
at 0.8 mg/mouse. (A) After 2, 6, 24, and 48 h, the levels of
hemopexin in the plasma of treated mice were examined by ELISA.
The plasma levels of (B) haptoglobin and (C) SAA were determined
by ELISA after 24 h. Data are presented as mean± SEM. (n= 5;
Double asterisks denote P< 0.01 versus the value for the
saline-treated group by ANOVA, single hash denotes P< 0.05, and
double hash denote P< 0.01 versus the value for the nSP70-treated
group by ANOVA).
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hemolytic activity of silica particles is related to surface
characteristics such as area and curvature [33-35]. How-
ever, we found that nSP70 at 0.8 mg/mouse does not in-
duce hemolytic activity through elevation of haptoglobin
and hemopexin (Figure 3). We are continuing investiga-
tions to understand the biological mechanisms asso-
ciated with the elevation of hemopexin after exposure to
silica nanoparticles.
We then examined the effects of surface modification
of silica nanoparticles on the production of hemopexin.
Compared to controls, hemopexin was not induced by
nSP70-N but was induced to a significantly higher level
by nSP70-C, which was a similar level to that induced
by unmodified nSP70 (Figure 4A). On the other hand,
the plasma levels of haptoglobin (Figure 4B) and SAA
(Figure 4C) in mice treated with nSP70-C were signifi-
cantly lower than those in mice treated with nSP70, as
reported previously [17]. These results suggest that the
production of acute-phase proteins depends on the char-
acteristics of the nanomaterials and that nSP70-C
induces some biological effects associated with the
elevation of hemopexin. Increased hemopexin levels
have been found in patients with diabetes mellitus
and are associated with some malignancies, such as
malignant melanoma and breast cancer [20,36,37].
Elevated hemopexin levels have also been found in
inflammatory psychiatric disorders, such as major de-
pression, schizophrenia, and mania [38]. Taken together,
these findings suggest that hemopexin might be asso-
ciated with these diseases so it is possible that the
induced elevation of hemopexin by both nSP70 and
nSP70-C is related to the induction of inflammatory
responses. Therefore, we are currently analyzing not
only the mechanisms underlying the differences in pro-
duction of hemopexin, haptoglobin, and SAA induced
by nSP70-C and nSP70, but also the relationship. It
could be speculated that there are differences between
the fates of the injected nSP70 and nSP70-C. Therefore,
there is a need to evaluate the distribution or accumula-
tion of the injected nanoparticles in the liver where
acute-phase proteins are known to be produced. An
understanding of these mechanisms will advance the use
of biomarkers for different purposes and improve the
predictive value of these biomarkers.
Hemopexin is one of the acute-phase proteins released
from the liver, and its production is known to be regu-
lated by cytokines. For instance, interleukin (IL)-6 and
IL-22 induce the hepatic production of circulating SAA
[39,40]. Furthermore, it is conceivable that instead of in-
flammatory cytokines, small silica particles act directly
on the liver to induce the release of acute-phase pro-
teins. However, nSP70, at this dose, did not induce any
significant elevation of liver injury or dysfunction
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why nanomaterials induce the production of acute-phase
proteins. We are currently analyzing the detailed mech-
anism by which silica particles induce acute-phase
proteins.
Conclusions
We demonstrated that 2D-DIGE analysis is a useful ap-
proach for identifying novel biomarkers of nanomater-
ials. Using this approach, we identified hemopexin as a
useful biomarker and showed here that hemopexin can
act as a useful biomarker for analyzing the biological
responses associated with exposure to silica nanoparti-
cles. We believe that this study will contribute to the de-
velopment of biomarkers for ensuring the safety of silica
nanoparticles.
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